WallStSmart

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)vsJohnson & Johnson (JNJ)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Johnson & Johnson generates 588917% more annual revenue ($96.36B vs $16.36M). JNJ leads profitability with a 21.8% profit margin vs -4.3%. JNJ earns a higher WallStSmart Score of 59/100 (C).

HKPD

Avoid

22

out of 100

Grade: F

Growth: 4.7Profit: 2.5Value: 6.7Quality: 5.0

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

HKPDUndervalued (+81.4%)

Margin of Safety

+81.4%

Fair Value

$4.29

Current Price

$0.63

$3.67 discount

UndervaluedFair: $4.29Overvalued
JNJSignificantly Overvalued (-43.5%)

Margin of Safety

-43.5%

Fair Value

$160.13

Current Price

$229.85

$69.72 premium

UndervaluedFair: $160.13Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HKPD1 strengths · Avg: 10.0/10
Price/BookValuation
1.3x10/10

Reasonable price relative to book value

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$547.28B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
26.4%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
21.8%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

Areas to Watch

HKPD4 concerns · Avg: 2.5/10
Market CapQuality
$15.52M3/10

Smaller company, higher risk/reward

Operating MarginProfitability
3.0%3/10

Operating margin of 3.0%

Return on EquityProfitability
-13.4%2/10

ROE of -13.4% — below average capital efficiency

Revenue GrowthGrowth
-35.7%2/10

Revenue declined 35.7%

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
26.3x4/10

Moderate valuation

PEG RatioValuation
2.962/10

Expensive relative to growth rate

EPS GrowthGrowth
-52.9%2/10

Earnings declined 52.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : HKPD

The strongest argument for HKPD centers on Price/Book.

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.

Bear Case : HKPD

The primary concerns for HKPD are Market Cap, Operating Margin, Return on Equity.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

HKPD profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.

JNJ is growing revenue faster at 9.9% — sustainability is the question.

JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

JNJ scores higher overall (59/100 vs 22/100), backed by strong 21.8% margins. HKPD offers better value entry with a 81.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Hong Kong Pharma Digital Technology Holdings Limited is a pioneering company at the intersection of biotechnology and digital healthcare, focusing on the integration of cutting-edge technology with pharmaceutical services to enhance patient outcomes and streamline healthcare delivery. Leveraging advanced digital solutions and data analytics, the company optimizes drug development processes and improves operational efficiencies, positioning itself as a critical player in the evolving healthcare landscape. With a strong commitment to health technology advancement and the cultivation of strategic alliances, Hong Kong Pharma is poised to meet the demands of both domestic and global markets while driving innovation across its pharmaceutical service offerings.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Want to dig deeper into these stocks?